Price List - Otulfi - TIB - IL23.xlsx

XLSX spreadsheet 50 KB Posted

Attached to
Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
Solicitation number
HT9402-25-Q-9203
Issued by

About this file

This file is a Price List for the Department of Defense (DoD) Uniform Formulary Blanket Purchase Agreement for Targeted Immunomodulatory Biologics, specifically the Interleukin 23 subclass, for the May 2025 P&T Committee Meeting. The solicitation (HT9402-25-Q-9203) involves pharmaceutical agents with quotes due on April 17, 2025, for potential inclusion in the TRICARE pharmacy benefit program. The document includes multiple appendices for newly approved drugs, covering various formulary scenarios such as Uniform Formulary (UF), Tier 2, and Tier 3 classifications, with specific provisions for step therapy and prior authorization.

Key details include potential prior authorization requirements, the possibility of preferential status or exclusion from the TRICARE pharmacy benefit, and a complex pricing and refund structure involving Federal Ceiling Price (FCP), non-FAMP (Federal Average Manufacturer Price), and Wholesale Acquisition Cost (WAC) calculations. The P&T Committee will consider removing step preferences for certain indications and may adjust formulary status based on submitted quotes. The solicitation covers multiple drugs in the Targeted Immunomodulatory Biologics class, with the Defense Health Agency conducting the procurement process to establish an efficient, integrated pharmacy benefits program for the Military Health System.

View the file

Other files

Show all 16

On GovTribe

Work with this file

  • Download the original file
  • Contacts named in this file
  • Similar government files
  • Ask GovTribe AI about this file

Text version

BPA

UF BPA NDC Price List for the May 2025 DoD P&T Meeting
DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 7-8, 2025
DOD Uniform Formulary Subclass:INTERLEUKIN 23Quotes due:April 17, 2025
Formulary Notes
Class Note(s): Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The DoD P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the DoD P&T Committee may identify candidates to recommend for complete exclusion from the TRICARE pharmacy benefit program.

Step Therapy Addendum: Grandfathering: a prior authorization process requires new patients to complete an adequate trial of the step-preferred agent(s) before a non-step-preferred agent is provided to the patient at any MTF, Retail, or Mail point of service.

Biosimilar Step Therapy Addendum: Since biosimilars are equivalent to the reference product, no grandfathering will apply. No Grandfathering: a prior authorization may process require new and current patients to complete an adequate trial of the step-preferred biosimilar(s) before a non-step-preferred biosimilar is provided to the patient at any MTF, Retail, or Mail point of service.

All Scenarios:

•P&T Committee will consider removing the TIBS class step preference (i.e., adalimumab) for select indications (e.g., psoriasis, IBD).
•Agents with RFQ not submitted or selected may be designated non-step preferred.

Notes to Manufacturers: Do not forget to submit fully executed signature pages along with quote information.

The price per unit of measure for a given dosage form and strength (each, gram, mL, etc.) of the pharmaceutical agent will be the same for all available package sizes (e.g., 30s, 100s, 1000s) within a given dispensing venue.

Blanket Purchase Agreement Appendix – Newly Approved Drug

#1DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 7-8, 2025
DOD Uniform Formulary Subclass:INTERLEUKIN 23Quotes due:April 17, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
One agent UF and before the step
Scenario 1251TB23G1UFBS1Uniform Formulary
Before Step Therapy1NO QUOTE
251TB23G1UFAS1MUniform Formulary
After Step Therapy1 or moreNO QUOTE
251TB23G1NFAS1MNon-Formulary
After Step Therapy1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote.

Blanket Purchase Agreement Appendix – Newly Approved Drug

#2DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 7-8, 2025
DOD Uniform Formulary Subclass:INTERLEUKIN 23Quotes due:April 17, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
One agent UF and before the step
Scenario 1251TB23G1UFBS1Uniform Formulary
Before Step Therapy1NO QUOTE
251TB23G1UFAS1MUniform Formulary
After Step Therapy1 or moreNO QUOTE
251TB23G1NFAS1MNon-Formulary
After Step Therapy1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote.
Blanket Purchase Agreement Appendix – Newly Approved Drug
#3DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 7-8, 2025
DOD Uniform Formulary Subclass:INTERLEUKIN 23Quotes due:April 17, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
One agent UF and before the step
Scenario 1251TB23G1UFBS1Uniform Formulary
Before Step Therapy1NO QUOTE
251TB23G1UFAS1MUniform Formulary
After Step Therapy1 or moreNO QUOTE
251TB23G1NFAS1MNon-Formulary
After Step Therapy1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote.

Blanket Purchase Agreement Appendix – Newly Approved Drug

#4DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 7-8, 2025
DOD Uniform Formulary Subclass:INTERLEUKIN 23Quotes due:April 17, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
One agent UF and before the step
Scenario 1251TB23G1UFBS1Uniform Formulary
Before Step Therapy1NO QUOTE
251TB23G1UFAS1MUniform Formulary
After Step Therapy1 or moreNO QUOTE
251TB23G1NFAS1MNon-Formulary
After Step Therapy1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote.
Blanket Purchase Agreement Appendix – Newly Approved Drug
#5DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 7-8, 2025
DOD Uniform Formulary Subclass:INTERLEUKIN 23Quotes due:April 17, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
One agent UF and before the step
Scenario 1251TB23G1UFBS1Uniform Formulary
Before Step Therapy1NO QUOTE
251TB23G1UFAS1MUniform Formulary
After Step Therapy1 or moreNO QUOTE
251TB23G1NFAS1MNon-Formulary
After Step Therapy1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote.

Blanket Purchase Agreement Appendix – Newly Approved Drug

#6DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 7-8, 2025
DOD Uniform Formulary Subclass:INTERLEUKIN 23Quotes due:April 17, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
One agent UF and before the step
Scenario 1251TB23G1UFBS1Uniform Formulary
Before Step Therapy1NO QUOTE
251TB23G1UFAS1MUniform Formulary
After Step Therapy1 or moreNO QUOTE
251TB23G1NFAS1MNon-Formulary
After Step Therapy1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote.

Blanket Purchase Agreement Appendix – Newly Approved Drug

#7DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 7-8, 2025
DOD Uniform Formulary Subclass:INTERLEUKIN 23Quotes due:April 17, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
One agent UF and before the step
Scenario 1251TB23G1UFBS1Uniform Formulary
Before Step Therapy1NO QUOTE
251TB23G1UFAS1MUniform Formulary
After Step Therapy1 or moreNO QUOTE
251TB23G1NFAS1MNon-Formulary
After Step Therapy1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote.

Blanket Purchase Agreement Appendix – Newly Approved Drug

#8DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 7-8, 2025
DOD Uniform Formulary Subclass:INTERLEUKIN 23Quotes due:April 17, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
One agent UF and before the step
Scenario 1251TB23G1UFBS1Uniform Formulary
Before Step Therapy1NO QUOTE
251TB23G1UFAS1MUniform Formulary
After Step Therapy1 or moreNO QUOTE
251TB23G1NFAS1MNon-Formulary
After Step Therapy1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote.
Blanket Purchase Agreement Appendix – Newly Approved Drug
#9DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 7-8, 2025
DOD Uniform Formulary Subclass:INTERLEUKIN 23Quotes due:April 17, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
One agent UF and before the step
Scenario 1251TB23G1UFBS1Uniform Formulary
Before Step Therapy1NO QUOTE
251TB23G1UFAS1MUniform Formulary
After Step Therapy1 or moreNO QUOTE
251TB23G1NFAS1MNon-Formulary
After Step Therapy1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote.
Blanket Purchase Agreement Appendix – Newly Approved Drug
#10DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 7-8, 2025
DOD Uniform Formulary Subclass:INTERLEUKIN 23Quotes due:April 17, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
One agent UF and before the step
Scenario 1251TB23G1UFBS1Uniform Formulary
Before Step Therapy1NO QUOTE
251TB23G1UFAS1MUniform Formulary
After Step Therapy1 or moreNO QUOTE
251TB23G1NFAS1MNon-Formulary
After Step Therapy1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote.

ADP (non-FAMP Discount)

UF ADP Appendix for the May 2025 DoD P&T Meeting
DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 7-8, 2025
DOD Uniform Formulary Subclass:INTERLEUKIN 23Quotes due:April 17, 2025
Formulary Notes
Class Note(s): Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The DoD P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the DoD P&T Committee may identify candidates to recommend for complete exclusion from the TRICARE pharmacy benefit program.

Step Therapy Addendum: Grandfathering: a prior authorization process requires new patients to complete an adequate trial of the step-preferred agent(s) before a non-step-preferred agent is provided to the patient at any MTF, Retail, or Mail point of service.

Biosimilar Step Therapy Addendum: Since biosimilars are equivalent to the reference product, no grandfathering will apply. No Grandfathering: a prior authorization process may require new and current patients to complete an adequate trial of the step-preferred biosimilar(s) before a non-step-preferred biosimilar is provided to the patient at any MTF, Retail, or Mail point of service.

All Scenarios:

•P&T Committee will consider removing the TIBS class step preference (i.e., adalimumab) for select indications (e.g., psoriasis, IBD).
•Agents with RFQ not submitted or selected may be designated non-step preferred.

Notes to Manufacturers: Do not forget to submit fully executed signature pages along with quote information.

* Total Calculated Refund Per FCP is calculated as: ((non-FAMP-FCP)+(non-FAMP*Y%)) = Total Calculated Refund **Based on the most recent annual non-FAMP (reported to the Department of Veterans Affairs) from which the current annual Federal Ceiling Price (FCP) calculated ceiling is derived. The current annual FCP and the annual non-FAMP from which it is derived will be applicable to all prescriptions filled during a calendar year. The quoted additional refund percentage will remain static during the life of the agreement but the most recent annual non-FAMP, and thus the calculated refund, may change each calendar year.

Additional Discount Program Appendix – Newly Approved Drug

#1DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 7-8, 2025
DOD Uniform Formulary Subclass:INTERLEUKIN 23Quotes due:April 17, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
One agent T2 and before the step
Scenario 1251TB23G1T2BS1Tier 2
Before Step Therapy1
251TB23G1T2AS1MTier 2
After Step Therapy1 or more
251TB23G1T3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote.

Additional Discount Program Appendix – Newly Approved Drug

#2DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 7-8, 2025
DOD Uniform Formulary Subclass:INTERLEUKIN 23Quotes due:April 17, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
One agent T2 and before the step
Scenario 1251TB23G1T2BS1Tier 2
Before Step Therapy1
251TB23G1T2AS1MTier 2
After Step Therapy1 or more
251TB23G1T3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote.

Additional Discount Program Appendix – Newly Approved Drug

#3DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 7-8, 2025
DOD Uniform Formulary Subclass:INTERLEUKIN 23Quotes due:April 17, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
One agent T2 and before the step
Scenario 1251TB23G1T2BS1Tier 2
Before Step Therapy1
251TB23G1T2AS1MTier 2
After Step Therapy1 or more
251TB23G1T3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote.

Additional Discount Program Appendix – Newly Approved Drug

#4DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 7-8, 2025
DOD Uniform Formulary Subclass:INTERLEUKIN 23Quotes due:April 17, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
One agent T2 and before the step
Scenario 1251TB23G1T2BS1Tier 2
Before Step Therapy1
251TB23G1T2AS1MTier 2
After Step Therapy1 or more
251TB23G1T3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote.

Additional Discount Program Appendix – Newly Approved Drug

#5DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 7-8, 2025
DOD Uniform Formulary Subclass:INTERLEUKIN 23Quotes due:April 17, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
One agent T2 and before the step
Scenario 1251TB23G1T2BS1Tier 2
Before Step Therapy1
251TB23G1T2AS1MTier 2
After Step Therapy1 or more
251TB23G1T3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote.

Additional Discount Program Appendix – Newly Approved Drug

#6DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 7-8, 2025
DOD Uniform Formulary Subclass:INTERLEUKIN 23Quotes due:April 17, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
One agent T2 and before the step
Scenario 1251TB23G1T2BS1Tier 2
Before Step Therapy1
251TB23G1T2AS1MTier 2
After Step Therapy1 or more
251TB23G1T3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote.

Additional Discount Program Appendix – Newly Approved Drug

#7DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 7-8, 2025
DOD Uniform Formulary Subclass:INTERLEUKIN 23Quotes due:April 17, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
One agent T2 and before the step
Scenario 1251TB23G1T2BS1Tier 2
Before Step Therapy1
251TB23G1T2AS1MTier 2
After Step Therapy1 or more
251TB23G1T3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote.

Additional Discount Program Appendix – Newly Approved Drug

#8DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 7-8, 2025
DOD Uniform Formulary Subclass:INTERLEUKIN 23Quotes due:April 17, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
One agent T2 and before the step
Scenario 1251TB23G1T2BS1Tier 2
Before Step Therapy1
251TB23G1T2AS1MTier 2
After Step Therapy1 or more
251TB23G1T3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote.

Additional Discount Program Appendix – Newly Approved Drug

#9DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 7-8, 2025
DOD Uniform Formulary Subclass:INTERLEUKIN 23Quotes due:April 17, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
One agent T2 and before the step
Scenario 1251TB23G1T2BS1Tier 2
Before Step Therapy1
251TB23G1T2AS1MTier 2
After Step Therapy1 or more
251TB23G1T3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote.

Additional Discount Program Appendix – Newly Approved Drug

#10DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 7-8, 2025
DOD Uniform Formulary Subclass:INTERLEUKIN 23Quotes due:April 17, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
One agent T2 and before the step
Scenario 1251TB23G1T2BS1Tier 2
Before Step Therapy1
251TB23G1T2AS1MTier 2
After Step Therapy1 or more
251TB23G1T3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote.

ADP (WAC Discount)

UF ADP Appendix for the May 2025 DoD P&T Meeting
DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 7-8, 2025
DOD Uniform Formulary Subclass:INTERLEUKIN 23Quotes due:April 17, 2025
Formulary Notes
Class Note(s): Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The DoD P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the DoD P&T Committee may identify candidates to recommend for complete exclusion from the TRICARE pharmacy benefit program.

Step Therapy Addendum: Grandfathering: a prior authorization process requires new patients to complete an adequate trial of the step-preferred agent(s) before a non-step-preferred agent is provided to the patient at any MTF, Retail, or Mail point of service.

Biosimilar Step Therapy Addendum: Since biosimilars are equivalent to the reference product, no grandfathering will apply. No Grandfathering: a prior authorization process may require new and current patients to complete an adequate trial of the step-preferred biosimilar(s) before a non-step-preferred biosimilar is provided to the patient at any MTF, Retail, or Mail point of service.

All Scenarios:

•P&T Committee will consider removing the TIBS class step preference (i.e., adalimumab) for select indications (e.g., psoriasis, IBD).
•Agents with RFQ not submitted or selected may be designated non-step preferred.

Notes to Manufacturers: Do not forget to submit fully executed signature pages along with quote information.

The Wholesale Acquisition Cost (WAC) is obtained from First Databank via daily price updates; it is maintained at the dispensing unit level to five (5) decimal places. If the WAC changes during a calendar quarter, an average WAC will be calculated on a daily weighted basis (per unit only).

WAC is ONLY used for products that do not have a FCP, such as diabetic supplies (i.e., test strips), and can also be applied to covered drugs.

*The quoted WAC Discount percentage will remain static during the life of the agreement.

Additional Discount Program Appendix – Newly Approved Drug

#1DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 7-8, 2025
DOD Uniform Formulary Subclass:INTERLEUKIN 23Quotes due:April 17, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Brand AgentsWAC Price of DrugWAC Discount*Total Calculated Retail Refund per Package
One agent T2 and before the step
Scenario 1251TB23G1T2BS1Tier 2
Before Step Therapy1
251TB23G1T2AS1MTier 2
After Step Therapy1 or more
251TB23G1T3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote.

Additional Discount Program Appendix – Newly Approved Drug

#2DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 7-8, 2025
DOD Uniform Formulary Subclass:INTERLEUKIN 23Quotes due:April 17, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Brand AgentsWAC Price of DrugWAC Discount*Total Calculated Retail Refund per Package
One agent T2 and before the step
Scenario 1251TB23G1T2BS1Tier 2
Before Step Therapy1
251TB23G1T2AS1MTier 2
After Step Therapy1 or more
251TB23G1T3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote.

Additional Discount Program Appendix – Newly Approved Drug

#3DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 7-8, 2025
DOD Uniform Formulary Subclass:INTERLEUKIN 23Quotes due:April 17, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Brand AgentsWAC Price of DrugWAC Discount*Total Calculated Retail Refund per Package
One agent T2 and before the step
Scenario 1251TB23G1T2BS1Tier 2
Before Step Therapy1
251TB23G1T2AS1MTier 2
After Step Therapy1 or more
251TB23G1T3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote.

Additional Discount Program Appendix – Newly Approved Drug

#4DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 7-8, 2025
DOD Uniform Formulary Subclass:INTERLEUKIN 23Quotes due:April 17, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Brand AgentsWAC Price of DrugWAC Discount*Total Calculated Retail Refund per Package
One agent T2 and before the step
Scenario 1251TB23G1T2BS1Tier 2
Before Step Therapy1
251TB23G1T2AS1MTier 2
After Step Therapy1 or more
251TB23G1T3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote.

Additional Discount Program Appendix – Newly Approved Drug

#5DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 7-8, 2025
DOD Uniform Formulary Subclass:INTERLEUKIN 23Quotes due:April 17, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Brand AgentsWAC Price of DrugWAC Discount*Total Calculated Retail Refund per Package
One agent T2 and before the step
Scenario 1251TB23G1T2BS1Tier 2
Before Step Therapy1
251TB23G1T2AS1MTier 2
After Step Therapy1 or more
251TB23G1T3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote.

Additional Discount Program Appendix – Newly Approved Drug

#6DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 7-8, 2025
DOD Uniform Formulary Subclass:INTERLEUKIN 23Quotes due:April 17, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Brand AgentsWAC Price of DrugWAC Discount*Total Calculated Retail Refund per Package
One agent T2 and before the step
Scenario 1251TB23G1T2BS1Tier 2
Before Step Therapy1
251TB23G1T2AS1MTier 2
After Step Therapy1 or more
251TB23G1T3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote.

Additional Discount Program Appendix – Newly Approved Drug

#7DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 7-8, 2025
DOD Uniform Formulary Subclass:INTERLEUKIN 23Quotes due:April 17, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Brand AgentsWAC Price of DrugWAC Discount*Total Calculated Retail Refund per Package
One agent T2 and before the step
Scenario 1251TB23G1T2BS1Tier 2
Before Step Therapy1
251TB23G1T2AS1MTier 2
After Step Therapy1 or more
251TB23G1T3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote.

Additional Discount Program Appendix – Newly Approved Drug

#8DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 7-8, 2025
DOD Uniform Formulary Subclass:INTERLEUKIN 23Quotes due:April 17, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Brand AgentsWAC Price of DrugWAC Discount*Total Calculated Retail Refund per Package
One agent T2 and before the step
Scenario 1251TB23G1T2BS1Tier 2
Before Step Therapy1
251TB23G1T2AS1MTier 2
After Step Therapy1 or more
251TB23G1T3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote.

Additional Discount Program Appendix – Newly Approved Drug

#9DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 7-8, 2025
DOD Uniform Formulary Subclass:INTERLEUKIN 23Quotes due:April 17, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Brand AgentsWAC Price of DrugWAC Discount*Total Calculated Retail Refund per Package
One agent T2 and before the step
Scenario 1251TB23G1T2BS1Tier 2
Before Step Therapy1
251TB23G1T2AS1MTier 2
After Step Therapy1 or more
251TB23G1T3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote.

Additional Discount Program Appendix – Newly Approved Drug

#10DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 7-8, 2025
DOD Uniform Formulary Subclass:INTERLEUKIN 23Quotes due:April 17, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Brand AgentsWAC Price of DrugWAC Discount*Total Calculated Retail Refund per Package
One agent T2 and before the step
Scenario 1251TB23G1T2BS1Tier 2
Before Step Therapy1
251TB23G1T2AS1MTier 2
After Step Therapy1 or more
251TB23G1T3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote.

File details come from the government source that posted it. Updated .